Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy

Trial Profile

Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2015

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Central serous chorioretinopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 15 Jan 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 15 Jan 2015 Planned primary completion date changed to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top